Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome
We present here a patient with NS with a PTPN11 mutation and an optic pathway pilomyxoid astrocytoma. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc. (Source: Pediatric Blood and Cancer)
Source: Pediatric Blood and Cancer - January 13, 2015 Category: Cancer & Oncology Authors: Sushmita Nair, John A. Fort, Anthony T. Yachnis, Charles A. Williams Tags: Brief Report Source Type: research
Gliomas in the Sellar Turcica Region: A Retrospective Study Including Adult Cases and Comparison with Craniopharyngioma
Conclusions: Sellar gliomas affect both pediatric and adult patients with pathological changes extending beyond pilocytic astrocytomas. They have diverse clinical manifestations and imaging presentations. Differences exist regarding several aspects between sellar gliomas and craniopharyngiomas, which may facilitate a differential diagnosis.Eur Neurol 2015;73:135-143 (Source: European Neurology)
Source: European Neurology - December 19, 2014 Category: Neurology Source Type: research
Pilomyxoid astrocytoma (PMA) shows significant differences in gene expression versus pilocytic astrocytoma (PA) and variable tendency toward maturation to PA
Abstract
Pilomyxoid astrocytomas (PMAs) manifest a more aggressive clinical course than pilocytic astrocytomas (PAs). Development of effective therapies demands a better biological understanding of PMA. We first conducted gene expression microarray analysis of 9 PMA and 13 PA from infra‐ and supra‐tentorial sites. Unsupervised hierarchical clustering analysis demonstrated that tumors grouped according to anatomic site, not diagnosis. Gene expression profiles were then contrasted between 8 PMAs and 6 PAs, all supratentorial/hypothalamic/chiasmal. Clinical outcome of PMAs varied, with 4/4 patients with diencephalic syndr...
Source: Brain Pathology - December 17, 2014 Category: Neurology Authors: B.K. Kleinschmidt‐DeMasters, Andrew M. Donson, Hannes Vogel, Nicholas K. Foreman Tags: Research Article Source Type: research
Pilomyxoid astrocytoma in an elderly patient: A case report and review of literature
R Amita, S Sandhyamani, Suresh Nair, TR KapilamoorthyNeurology India 2014 62(5):549-551 (Source: Neurology India)
Source: Neurology India - November 12, 2014 Category: Neurology Authors: R AmitaS SandhyamaniSuresh NairTR Kapilamoorthy Source Type: research
Pilomyxoid astrocytoma treated successfully with vemurafenib
We report a patient with a BRAF V600E mutated pilomyxoid astrocytoma who failed multiple conventional chemotherapy regimens. Treatment with vemurafenib, a molecularly targeted therapy against the mutant BRAF V600E kinase, combined with vinblastine resulted in tumor regression. Furthermore, this patient experienced almost immediate progression of disease after holding vemurafenib for only 2–3 weeks, suggesting that the tumor response is vemurafenib dependent. This population of patients may benefit from targeted therapy and testing of individual tumors for BRAF mutations is justified. Pediatr Blood Cancer © 2014 Wiley Pe...
Source: Pediatric Blood and Cancer - May 13, 2014 Category: Cancer & Oncology Authors: Mary Skrypek, Nicholas Foreman, Daniel Guillaume, Christopher Moertel Tags: Brief Report Source Type: research
Pilomyxoid astrocytoma of the pineal region
This report shows that smear preparation can be trustworthy for the intraoperative diagnosis of PMA, helping to determine the appropriate neurosurgical procedure and therapeutic implications. Diagn. Cytopathol. 2014. © 2014 Wiley Periodicals, Inc. (Source: Diagnostic Cytopathology)
Source: Diagnostic Cytopathology - February 28, 2014 Category: Pathology Authors: Toshitetsu Hayashi, Reiji Haba, Yoshio Kushida, Naomi Katsuki, Shinsuke Shibuya, Kyuichi Kadota, Toru Matsunaga, Keisuke Miyake, Takashi Tamiya Tags: Brief Report Source Type: research
Pilomyxoid astrocytoma of the pineal region: Cytopathological features and differential diagnostic considerations by intraoperative smear preparation
This report shows that smear preparation can be trustworthy for the intraoperative diagnosis of PMA, helping to determine the appropriate neurosurgical procedure and therapeutic implications. Diagn. Cytopathol. 2015;43:121–124. © 2014 Wiley Periodicals, Inc. (Source: Diagnostic Cytopathology)
Source: Diagnostic Cytopathology - February 28, 2014 Category: Pathology Authors: Toshitetsu Hayashi, Reiji Haba, Yoshio Kushida, Naomi Katsuki, Shinsuke Shibuya, Kyuichi Kadota, Toru Matsunaga, Keisuke Miyake, Takashi Tamiya Tags: Brief Report Source Type: research
Primary pilomyxoid astrocytoma of the thoracolumbar spinal cord in an adult
Liang Wu, Tao Yang, Chenlong Yang, Yulun XuNeurology India 2013 61(6):677-679 (Source: Neurology India)
Source: Neurology India - January 20, 2014 Category: Neurology Authors: Liang WuTao YangChenlong YangYulun Xu Source Type: research
Children
ConclusionsChildren <1 year at diagnosis have a conspicuously impaired survival with current treatment approaches. Age <6 months, diencephalic syndrome and dissemination constitute risk factors for even lower PFS and OS. Treatment adaptations are needed to improve outcome and molecular genetics may explain tumor aggressiveness. Pediatr Blood Cancer © 2013 Wiley Periodicals, Inc. (Source: Pediatric Blood and Cancer)
Source: Pediatric Blood and Cancer - September 4, 2013 Category: Cancer & Oncology Authors: Cora Mirow, Torsten Pietsch, Susanne Berkefeld, Robert Kwiecien, Monika Warmuth‐Metz, Fabian Falkenstein, Barbara Diehl, Stephan von Hornstein, Astrid K. Gnekow Tags: Research Article Source Type: research
Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Expression Is an Independent Prognostic Factor in Pediatric Pilocytic and Pilomyxoid Astrocytoma
This study aimed to determine the expression and prognostic value of IMP3 in pediatric PA/PMAs. Insulin-like growth factor 2 mRNA binding protein 3 protein expression was examined by immunohistochemistry in 77 pediatric PAs (n = 70) and PMAs (n = 7) and scored on a subjective scale. Strong diffuse staining for IMP3 was observed in 31% (24 of 77) of tumors and associated with a shorter progression-free survival (hazard ratio, 2.63; p = 0.008). This cohort confirmed previously identified prognostic factors, including extent of resection, age, and tumor location. Currently, only clinical factors are weighed to stratify risk f...
Source: Journal of Neuropathology and Experimental Neurology - May 1, 2013 Category: Neurology Tags: Original Articles Source Type: research
The molecular biology of WHO Grade II gliomas.
Abstract
The WHO grading scheme for glial neoplasms assigns Grade II to 5 distinct tumors of astrocytic or oligodendroglial lineage: diffuse astrocytoma, oligodendroglioma, oligoastrocytoma, pleomorphic xanthoastrocytoma, and pilomyxoid astrocytoma. Although commonly referred to collectively as among the "low-grade gliomas," these 5 tumors represent molecularly and clinically unique entities. Each is the subject of active basic research aimed at developing a more complete understanding of its molecular biology, and the pace of such research continues to accelerate. Additionally, because managing and predic...
Source: Neurosurgical Focus - February 1, 2013 Category: Neurosurgery Authors: Marko NF, Weil RJ Tags: Neurosurg Focus Source Type: research
Differentiation between high and low grade tumours in paediatric patients by using apparent diffusion coefficients.
CONCLUSION: Combining the information obtained from conventional MR imaging with the ADC values may increase the accuracy of pre-operative differentiation between low grade and high grade paediatric tumours. Cut-off values can help to discern low from high grade tumours. However, it has to be considered that there is a substantial overlap between tumour types previously described in the literature.
PMID: 23273960 [PubMed - as supplied by publisher] (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - December 26, 2012 Category: Neurology Authors: Porto L, Jurcoane A, Schwabe D, Kieslich M, Hattingen E Tags: Eur J Paediatr Neurol Source Type: research
